Navigation Links
Novelos Therapeutics to Present at the 5th Lippert/Heilshorn Life Sciences & Medical Technologies Virtual Conference on June 16
Date:6/13/2011

MADISON, Wis., June 13, 2011 /PRNewswire/ -- Novelos Therapeutics, Inc. (OTCBB: NVLT), a pharmaceutical company developing novel drugs for treatment and diagnosis of cancer, today announced that Harry S. Palmin, President and CEO of Novelos, will present at the 5th  Lippert/Heilshorn Life Sciences & Medical Technologies Virtual Conference on Thursday, June 16, 2011, at 11:30 a.m. Eastern time.

The webcast of the Novelos presentation may be accessed at www.novelos.com

The webcast archive will be available for 90 days following the presentation.

This day-long virtual conference event includes 30-minute presentations with accompanying slides from nine industry leaders, and begins at 9:00 a.m. Eastern time.  The event may be accessed at the PrecisionIR event site www.vcall.com/CustomEvent/lipper/index.asp

About Novelos Therapeutics, Inc.We are a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer. We currently have three cancer-targeted compounds, which are selectively taken up and retained in cancer cells (including cancer stem cells) versus normal cells.  Thus, our therapeutic compounds directly kill cancer cells while minimizing harm to normal cells.  This offers the potential for a paradigm shift in cancer therapy – efficacy versus all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse.  LIGHT is a small-molecule cancer imaging agent.  We believe LIGHT has first-in-class potential and expect it to enter Phase 1/2 clinical trials in the third quarter of this year.  HOT is a small-molecule, broad-spectrum, cancer-targeted molecular radiotherapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells.  We believe HOT also has first-in-class potential, and we expe
'/>"/>

SOURCE Novelos Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Nonconformity of NOV002 Used in Phase 3 NSCLC Trial Sponsored by Novelos Therapeutics, Inc to NOV002 (Glutoxim(R)), Used in Phase 1/2 NSCLC and all Previous Trials
2. Grifols Announces Combined Operations With Talecris to Begin a New Era as a Global Leader of Life-Saving Plasma Therapeutics
3. Healthpoint Biotherapeutics to Present at Upcoming Investment Conferences
4. Selected Value Therapeutics Exercises Right to Develop and Commercialize ENMD-2076 in China
5. Precision Therapeutics Presents Clinical Study Emphasizing the Role of ChemoFx® in Directing Chemotherapy in Gynecological Cancers
6. Precision Therapeutics Demonstrates Utility of Multi-Gene Predictors in Predicting Chemotherapy Response for Breast Cancer Patients
7. Regulus Therapeutics and Collaborators from NYU Langone Medical Center Publish New Data Demonstrating Clearance of Cholesterol from Bloodstream and Reduction of Atherosclerotic Plaques through Inhibition of microRNA-33
8. Echo Therapeutics to Present at the Jefferies 2011 Global Healthcare Conference
9. Orexigen® Therapeutics Provides a Regulatory Update on Contrave® NDA
10. Goodwin Biotechnology Announces a Collaboration With Alethia Biotherapeutics
11. Serina Therapeutics, Inc. Closes $9.5 Million Financing Round
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... April 1, 2015 International Isotopes Inc. (OTCQB: ... year ended December 31, 2014.  The Company reports a ... loss, and positive cash flow for the year ended ... in 2014 was approximately $7.5 million compared to approximately ... approximately 10%.  With the exception of the radiological services ...
(Date:4/1/2015)... 2015 LifeScienceIndustryResearch.com announces ... Industry and 2015 Deep Research Report on ... Pharmaceutical category in its database.  ... basic information, including definition, classification, application, industry ... news analysis, etc. Azithromycin Key Manufacturers Analysis ...
(Date:4/1/2015)... -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ... on the development of oral drug delivery systems, announced ... Glucose Clamp Study. The study will be performed at ... San Antonio and University Health System,s ... Ralph DeFronzo . The glucose clamp is ...
Breaking Medicine Technology:International Isotopes Inc. Announces 2014 Year End Financial Results 2International Isotopes Inc. Announces 2014 Year End Financial Results 3International Isotopes Inc. Announces 2014 Year End Financial Results 4International Isotopes Inc. Announces 2014 Year End Financial Results 5International Isotopes Inc. Announces 2014 Year End Financial Results 6International Isotopes Inc. Announces 2014 Year End Financial Results 7Azithromycin Market & Polypeptide Drug Industry - Global Research Reports 2Azithromycin Market & Polypeptide Drug Industry - Global Research Reports 3Azithromycin Market & Polypeptide Drug Industry - Global Research Reports 4Azithromycin Market & Polypeptide Drug Industry - Global Research Reports 5Oramed Enrolls First Patient in its Glucose Clamp Study for Oral Insulin 2Oramed Enrolls First Patient in its Glucose Clamp Study for Oral Insulin 3
... Reportlinker.com announces that a new market research report is available ... http://www.reportlinker.com/p0324750/Virtual-Pharma.html ... in the pharmaceutical market has slowed – almost to a ... cutting costs in a faltering world economy. ...
... NEW YORK, Nov. 3, 2010 Pfizer Inc. (NYSE: ... public to view and listen to a webcast of ... Primary Care, at the 2010 Annual Credit Suisse Healthcare ... Mountain Standard Time. (Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO) ...
Cached Medicine Technology:Reportlinker Adds Virtual Pharma 2Reportlinker Adds Virtual Pharma 3Reportlinker Adds Virtual Pharma 4Reportlinker Adds Virtual Pharma 5Reportlinker Adds Virtual Pharma 6
(Date:4/1/2015)... Franklin University, one of the leading ... establishment of the Greta J. Russell Medical Mutual of ... the generous gift of $100,000 from Medical Mutual of ... Medical Mutual to University representatives, Dr. David Decker ... & Strategic Relations. , “We are grateful to ...
(Date:4/1/2015)... ScooterDirect.com is a one stop online store that ... lifestyle using electric mobility scooters, power chairs and portable ... people, they provide mobility scooters at an affordable price. ... their freedom. Scooterdirect.com is offering Pride Go Go Traveller ... , One of the team members quoted, “Pride Go ...
(Date:4/1/2015)... (PRWEB) April 01, 2015 Amercanex Corporation, ... of the American Cannabis Exchange and will conduct its ... Native Roots joins the exchange as one of the ... licenses and operating fifteen stores in 9 locations with ... , “We are excited to have Native Roots ...
(Date:4/1/2015)... 2015 The dearth of qualified ... set to retire in the next five years) ... for laboratory automation. The application of advanced technology ... ensures timely progress and efficiency with minimal errors. ... automation in high-throughput screening, combinatorial chemistry, automated clinical ...
(Date:4/1/2015)... 2015 When you’re suffering from back pain, ... some relief. Identifying the causes of lingering back or neck ... the cause of chronic back pain is due to facet ... causes of back pain and offers many possible treatments, according ... of Atlantic Spine Center . , Dr. Liu clarifies ...
Breaking Medicine News(10 mins):Health News:Franklin University Receives Gift to Create the Greta J. Russell Medical Mutual of Ohio Scholarship 2Health News:Franklin University Receives Gift to Create the Greta J. Russell Medical Mutual of Ohio Scholarship 3Health News:ScooterDirect.com Offering Pride Go Go Traveller Elite 3 Wheel Scooter 2Health News:Amercanex, Native Roots form Exclusive Relationship to facilitate Wholesale Business 2Health News:Amercanex, Native Roots form Exclusive Relationship to facilitate Wholesale Business 3Health News:Laboratory Accessories Market Worth $504.7 Million by 2020 – New Research Report by MarketsandMarkets 2Health News:Laboratory Accessories Market Worth $504.7 Million by 2020 – New Research Report by MarketsandMarkets 3Health News:Demystifying Facet Joint Syndrome 2Health News:Demystifying Facet Joint Syndrome 3Health News:Demystifying Facet Joint Syndrome 4
... ... ... ... ...
... ... ... , , ... ...
... ... ... , , ... ...
... ... ... , ... , , ...
... for Medicare-eligible patients enrolled in clinical trials; however, only ... non-Medicare patients, and these offer less protection than the ... special article published online March 2 in the ... In the United States, participants, costs for routine ...
... well controlled and on low doses of inhaled corticosteroids, ... of three possible step-up treatments. National Jewish clinician-scientists Stanley ... Taussig, and colleagues in the NIH-funded Childhood Asthma Research ... online in the New England Journal of Medicine ...
Cached Medicine News:Health News:Nominate Your Hometown Hero to Serve as ExtenZe Racing's Honorary Crew Chief at a 2010 NASCAR Sprint Cup Race 2Health News:Nominate Your Hometown Hero to Serve as ExtenZe Racing's Honorary Crew Chief at a 2010 NASCAR Sprint Cup Race 3Health News:Nominate Your Hometown Hero to Serve as ExtenZe Racing's Honorary Crew Chief at a 2010 NASCAR Sprint Cup Race 4Health News:2010 Caring Coalition Conference Welcomes Author Gail Sheehy 2Health News:2010 Caring Coalition Conference Welcomes Author Gail Sheehy 3Health News:OrthoDynamix LLC Receives FDA 510(k) Clearance for ArthroSteer(R) 3.5mm Ablator 2Health News:OrthoDynamix LLC Receives FDA 510(k) Clearance for ArthroSteer(R) 3.5mm Ablator 3Health News:Healthcare Trust of America, Inc. Executes Agreement to Acquire an Approximately 60,800 Square Foot Medical Office Building in Mount Pleasant, South Carolina 2Health News:Healthcare Trust of America, Inc. Executes Agreement to Acquire an Approximately 60,800 Square Foot Medical Office Building in Mount Pleasant, South Carolina 3Health News:Healthcare Trust of America, Inc. Executes Agreement to Acquire an Approximately 60,800 Square Foot Medical Office Building in Mount Pleasant, South Carolina 4Health News:State payer mandates to cover cancer trials offer heterogeneous protection for patients 2Health News:Long-acting beta-agonists most effective step-up therapy for children with poorly controlled asthma 2
... The E-Holder™ Platform is designed with a ... 96 and E-Gel® 48 gel cassettes stay ... allows reproducible placement and loading from one ... make adjustments to the robot loading software. ...
... are seamless eliminating the possibility of leakage around ... have temperature resistant gel trays meaning you do ... For added user friendliness, the Primo tanks come ... The Primo Gel Systems are designed to ...
Designed for rapid, routine electrophoresis for nucleic acids. The Mini unit is designed with a choice of two casting systems: standard casting trays that require sealing tape; or aluminum-gated cast...
... horizontal gel system is designed for very fast and ... This System allows the user to cast, run, and ... system with : 1 x electrophoresis tank and cover, ... x 83 mm tray), 2 x MT-T02 (50 x ...
Medicine Products: